5-Bromo-2-tert-butylpyrimidine

Catalog No.: 
ACEXFM349
CAS No.: 
85929-94-8
Molecular Formula: 
C8H11BrN2
Molecular Weight: 
215.09
5-Bromo-2-tert-butylpyrimidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$130.00In stockInquiry
250mg97%$243.00In stockInquiry
500mg97%$395.00In stockInquiry
1g97%$564.00In stockInquiry
5g97%$2254.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Bromo-2-tert-butylpyrimidine
IUPAC Name5-bromo-2-(tert-butyl)pyrimidine
MDL No.MFCD00235040
Molecular FormulaC8H11BrN2
Molecular Weight215.09
SMILESCC(C)(C)C1=NC=C(Br)C=N1
InChI KeyFAAQGONYZKWBKC-UHFFFAOYSA-N
Synonym5-Bromo-2-tert-butylpyrimidine, AldrichCPR | Pyrimidine, 5-bromo-2-(1,1-dimethylethyl)- | DTXSID10543150 | 5-BROMO-2-(TERT-BUTYL)PYRIMIDINE | SCHEMBL662800 | A863382 | AC-24511 | 5-Bromo-2-tert-butylpyrimidine | 2-TERT-BUTYL-5-BROMOPYRIMIDINE | AB05297 |
CAS No.85929-94-8
PubChem CID13532898

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACEXFM349 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACEXFM349 route product structure diagram
    ACEXFM34985929-94-8In Stock
Inquiry

2. ACEXFM349 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEXFM349 route product structure diagram
    ACEXFM34985929-94-8In Stock
Inquiry

3. ACEXFM349 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEXFM349 route product structure diagram
    ACEXFM34985929-94-8In Stock
Inquiry

Comments (0)